Results 31 to 40 of about 33,467 (159)
PLoS Neglected Tropical Diseases, 2022 Ribavirin is currently the standard of care for treating Lassa fever. However, the human clinical trial data supporting its use suffer from several serious flaws that render the results and conclusions unreliable.
Alex P Salam +7 more
doaj +1 more source
Crystallization Selectivity of Ribavirin Solution and Amorphous Phase
Molecules, 2023 Crystallization selectivity is an important principle in polymorph control. Ribavirin Form I, Form II, DMSO solvate, and amorphous ribavirin are prepared, and the short-range order similarities between these solid forms and ribavirin aqueous solution and
Fuying Li +6 more
doaj +1 more source
Reviews in Medical Virology, Volume 36, Issue 5, September 2026.ABSTRACT Hantaviruses are emerging zoonotic pathogens of increasing global public health significance. Their epidemiological landscape is rapidly changing due to ecological disruption, climate variability, urbanisation, and evolving human–animal interfaces.
Francesco De Maria +5 more
wiley +1 more source
BMC Gastroenterology, 2003 Background Evidence based medicine depends on unbiased selection of completed randomized controlled trials. For completeness it is important to publish all trials.
Delwaide Jean +7 more
doaj +1 more source
BMJ Open, 2020 Introduction Lassa fever (LF) is a severe and often fatal systemic disease in humans and affects a large number of countries in West Africa. Treatment options are limited to supportive care and the broad-spectrum antiviral agent ribavirin.
Michael Ramharter +16 more
doaj +1 more source
HCV‐Specific T‐Cell Recovery After a Year of SVR Following DAA Therapy
Journal of Medical Virology, Volume 98, Issue 8, August 2026.ABSTRACT Direct‐acting antiviral (DAA) drugs lead to sustained virologic response (SVR) in almost all treated patients with chronic hepatitis C virus (HCV) infection. Despite this success, the long‐term effects of HCV clearance by DAA therapy on T‐cell‐mediated antiviral immunity remain unclear, particularly concerning the restoration of immune ...
Tetiana Pozniak +9 more
wiley +1 more source
Emerging Infectious Diseases, 2018 We performed a systematic review and meta-analysis on the effectiveness of ribavirin use for the prevention of infection and death of healthcare workers exposed to patients with Crimean-Congo hemorrhagic fever virus (CCHFV) infection. Splashes with blood
Önder Ergönül +7 more
doaj +1 more source
Utilizing Virtual Clinical Trials to Inform Target Coverage That Drives RSV Antiviral Efficacy
CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 8, August 2026.ABSTRACT Respiratory syncytial virus (RSV) infection can result in a range of disease severity from mild upper respiratory tract symptoms to lower respiratory tract illness, with clinical manifestations dependent on age, co‐morbidities, and immune status.
J. Cody Herron +12 more
wiley +1 more source
Effect of Ribavirin on Hepatitis A Virus Replication In Vitro
Canadian Journal of Infectious Diseases, 1992 The effect of ribavirin on fetal Rhesus monkey kidney cells (FRhK-4) acutely or chronically infected with hepatitis A virus was studied. The effect of ribavirin on hepatitis A virus yield as detected by radioimmunoassay in acutely infected FRhK-4 cells ...
Rabindra K Chaudhary, Anton P Andonov
doaj +1 more source
Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection. [PDF]
PLoS ONE, 2016 In this pilot study (RibaC), 58 hepatitis C virus (HCV) genotype 1 infected treatment-naïve patients were randomized to (i) 2 weeks ribavirin double dosing concomitant with pegylated interferon-α (pegIFN-α), (ii) 4 weeks ribavirin mono-therapy prior to ...
Jesper Waldenström +13 more
doaj +1 more source